Literature DB >> 15923144

Malaria parasite transporters as a drug-delivery strategy.

Giancarlo A Biagini1, Stephen A Ward, Patrick G Bray.   

Abstract

The recent characterization of the choline carrier of the malaria parasite and its role in the selective delivery of novel antimalarial drugs has reignited interest in parasite transporters as a drug-delivery strategy. In this article, we discuss these findings in relation to the wider context of developing a sustainable antimalarial-drug-development portfolio.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15923144     DOI： 10.1016/j.pt.2005.05.013

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  10 in total

1.  Rodent and nonrodent malaria parasites differ in their phospholipid metabolic pathways.

Authors:  Sandrine Déchamps; Marjorie Maynadier; Sharon Wein; Laila Gannoun-Zaki; Eric Maréchal; Henri J Vial
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

Review 2.  Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies.

Authors:  Miloni Thakkar; Brijesh S
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

Review 3.  Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.

Authors:  Sindisiwe Mvango; William M R Matshe; Abideen O Balogun; Lynne A Pilcher; Mohammed O Balogun
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

4.  Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.

Authors:  Eric Richier; Giancarlo A Biagini; Sharon Wein; Frederic Boudou; Patrick G Bray; Steve A Ward; Eric Precigout; Michèle Calas; Jean-François Dubremetz; Henri J Vial
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Fluorescent Nitrogen-Doped Carbon Dots for Label Live Elder Blood-Stage Plasmodium falciparum through New Permeability Pathways.

Authors:  Jiahui Xu; Fengyue Hu; Shuang Li; Jiaojiao Bao; Yi Yin; Zhenyu Ren; Ying Deng; Fang Tian; Guangyu Bao; Jian Liu; Yinyue Li; Xinlong He; Juqun Xi; Feng Lu
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

6.  Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate.

Authors:  S Wein; M Maynadier; Y Bordat; J Perez; S Maheshwari; P Bette-Bobillo; C Tran Van Ba; D Penarete-Vargas; L Fraisse; R Cerdan; H Vial
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

7.  Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes.

Authors:  Gulam Mustafa Hasan; Neha Garg; Enna Dogra; Ranu Surolia; Prahlad Chandra Ghosh
Journal:  J Parasitol Res       Date:  2011-06-14

8.  Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14.

Authors:  Ruchi Gupta; Vinoth Rajendran; Prahlad C Ghosh; Sheela Srivastava
Journal:  Drugs R D       Date:  2014-06

9.  A Plasmodium falciparum copper-binding membrane protein with copper transport motifs.

Authors:  David L Choveaux; Jude M Przyborski; J P Dean Goldring
Journal:  Malar J       Date:  2012-11-29       Impact factor: 2.979

Review 10.  Medical relevance of UK-funded non-human primate research published from January 1997 to July 2012.

Authors:  Edward Moore
Journal:  J R Soc Med       Date:  2014-04-16       Impact factor: 5.344
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.